Table 2.
Percentages of different lymphocyte subsets in the CD4+ and CD8+ T cell population, in immune reconstitution inflammatory syndrome patients, clinical progressors and uninfected controls.
| CD4 | CD8 | ||
| IRIS | p value | ||
| HLA-DR | 27.4 (16–38.4) | 28.7 (24.6–32) | < 0.005/n.s |
| CD38 | 77 (70–78.5) | 82.6 (75.3–90.7) | n.s/< 0.05 |
| CD38 MFI | 1118 (1253-780) | 493 (548-297) | < 0.02/< 0.01 |
| Naïve | 19.4 (6.9–23.9) | 25 (7–42) | < 0.005/n.s |
| Memory | 85 (44–96) | 53.8 (37.5–76) | n.s/n.s |
| CP | |||
| HLA-DR | 7.3 (5.4–9.2) | 30.5 (22–40) | |
| CD38 | 66 (60.7–71.7) | 73 (61.7–80) | |
| CD38 MFI | 173 (85–211) | 133 (105–146) | |
| Naïve | 35 (30–45) | 32 (24.6–42) | |
| Memory | 59 (54–67) | 38 (26–46) | |
| UC | |||
| HLA-DR | 4 (2.8–5.3) | 7.6 (6.9–9.9) | |
| CD38 | 70 (68–75.5) | 66 (66–70) | |
| CD38 MFI | 97 (71–116) | 85 (58–87) | |
| Naïve | 40.8 (40–49) | 60.4 (51.2–61.5) | |
| Memory | 30 (29.2–40) | 22 (20.8–30.3) | |
IRIS- Immune reconstitution inflammatory syndrome patients; CP- asymptomatic clinical progressors; UC- uninfected controls. Data are shown as median percentage, and CD38 mean fluorescent intensity (MFI) (interquartile range). p values shown between IRIS and CP patients for CD4/CD8 data respectively.